Quantcast
Last updated on April 16, 2014 at 14:05 EDT

Latest Effector Stories

2013-05-20 08:26:35

Company to Focus on Small Molecule Selective Translation Regulators for Cancer SAN DIEGO, May 20, 2013 /PRNewswire/ -- eFFECTOR Therapeutics, a newly established biopharmaceutical company, today announced the completion of a $45 million Series A financing. eFFECTOR is focused on inventing and developing small molecule drugs to selectively regulate protein synthesis, also known as translation, with an initial emphasis on cancer. Series A investors include U.S. Venture Partners,...

2013-05-13 08:28:39

CARLSBAD, Calif., May 13, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) announced today the issuance of a new patent covering nucleic acids encoding Transcription Activator-Like Effector Nuclease fusion proteins (TALENS) and the formal launch of an associated sublicensing program. The technology has broad utility in the pharmaceutical industry, synthetic biology, and plant sciences for creating genetically modified cell lines, animals and plants, and is being actively...

2013-02-07 15:32:44

Research by UC Riverside plant pathologists is the first to show that RNA silencing regulates plant defense against the notorious Phytophthora pathogens When a pathogen attacks a plant, infection usually follows after the plant´s immune system is compromised. A team of researchers at the University of California, Riverside focused on Phytophthora, the pathogen that triggered the Irish Famine of the 19th century, and deciphered how it succeeded in crippling the potato plant´s...